Akebia Therapeutics (AKBA) Short term Debt (2018 - 2026)

Akebia Therapeutics (AKBA) has 5 years of Short term Debt data on file, last reported at $12.5 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $12.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $12.5 million (changed N/A YoY), and the FY2023 annual result was $17.5 million, down 45.31% from the prior year.
• Short term Debt slipped to $12.5 million in Q1 2026 per AKBA's latest filing, from $17.5 million in the prior quarter.
• Over five years, Short term Debt peaked at $98.2 million in Q2 2022 and troughed at $8.0 million in Q3 2023.
• A 3-year average of $42.2 million and a median of $24.0 million in 2023 frame the typical range for Short term Debt.
• On a YoY basis, Short term Debt climbed as much as 45.31% in 2023 and fell as far as 87.87% in 2023.
• A 3-year view of Short term Debt shows it stood at $32.0 million in 2022, then plunged by 45.31% to $17.5 million in 2023, then dropped by 28.6% to $12.5 million in 2026.
• Business Quant data shows AKBA's Short term Debt at $12.5 million in Q1 2026, $17.5 million in Q4 2023, and $8.0 million in Q3 2023.